Ipca Laboratories Limited

NSE:IPCALAB.NS

1454.35 (INR) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 77,050.462,443.257,664.653,409.545,58736,921.932,065.931,493.628,453.331,16632,469.927,737.723,587.318,825.415,595.512,83810,510.49,391.17,557.0196,790.316
Cost of Revenue 46,414.223,065.121,059.718,017.617,088.412,903.811,762.111,641.211,097.412,099.111,849.411,4609,131.27,764.26,4565,072.74,638.84,012.85,438.9044,743.507
Gross Profit 30,636.239,378.136,604.935,391.928,498.624,018.120,303.819,852.417,355.919,066.920,620.516,277.714,456.111,061.29,139.57,765.35,871.65,378.32,118.1152,046.809
Gross Profit Ratio 0.3980.6310.6350.6630.6250.6510.6330.630.610.6120.6350.5870.6130.5880.5860.6050.5590.5730.280.301
Reseach & Development Expenses 1,707.1461.3418523.8313.8207.4266.2416.8404.6402.6624.7355.4404.70000000
General & Administrative Expenses 1,174761.9736.5970.7585.8799.4808.1578.4487.9485.5391.5350.22,592.30000000
Selling & Marketing Expenses 7,086.35,561.73,696.82,988.63,315.62,940.62,525.62,597.12,137.82,4502,311.82,129.41,960.90000000
SG&A 22,253.26,323.64,433.33,959.33,901.43,7403,333.73,175.52,625.72,935.52,703.32,479.64,553.20000000
Other Expenses 1,247.71,256.2155.7144.8201.9210.7191.524.216.228.43623.311.87,340.36,183.76,264.13,915.13,610.51,239.3861,040.862
Operating Expenses 22,253.232,72625,978.322,186.821,051.918,667.517,467.917,196.615,575.815,372.413,474.610,857.39,934.27,340.36,183.76,264.13,915.13,610.51,239.3861,040.862
Operating Income 8,3837,033.510,590.613,145.97,421.15,314.52,835.92,655.81,780.13,694.57,145.95,420.44,521.93,720.92,955.81,501.21,956.51,767.8878.7291,005.947
Operating Income Ratio 0.1090.1130.1840.2460.1630.1440.0880.0840.0630.1190.220.1950.1920.1980.190.1170.1860.1880.1160.148
Total Other Income Expenses Net 43.7290555666.9-32.2150.169.447.4-627.1-83.7-840-877.7-878.8-314-293.2-318-203.9-224.7-133.726-64.814
Income Before Tax 8,426.77,452.911,357.213,812.87,388.95,464.62,905.32,703.21,1533,610.86,305.94,542.73,643.13,406.92,662.61,183.21,752.61,543.1745.003941.133
Income Before Tax Ratio 0.1090.1190.1970.2590.1620.1480.0910.0860.0410.1160.1940.1640.1540.1810.1710.0920.1670.1640.0990.139
Income Tax Expense 3,134.62,533.62,247.72,401.41,353.31,042.4511.1675.2185.71,019.31,523.91,299.4881.1783.8627.2232.5357.9293.8144.772238.258
Net Income 5,473.54,713.28,840.811,400.16,063.24,448.32,394.22,028967.32,591.54,7823,243.32,770.62,628.22,053.61,0081,359.31,261.7615.046740.85
Net Income Ratio 0.0710.0750.1530.2130.1330.120.0750.0640.0340.0830.1470.1170.1170.140.1320.0790.1290.1340.0810.109
EPS 21.5718.5834.8545.012417.619.497.713.6910.0718.9612.8310.9910.488.224.015.435.052.462.96
EPS Diluted 21.5718.5834.8545.0123.9817.619.497.713.6910.0718.9612.8310.9910.488.2145.415.032.462.96
EBITDA 11,955.410,523.913,716.516,085.69,808.67,416.14,877.14,646.13,120.85,6627,538.85,688.55,276.34,278.83,452.61,897.82,281.62,046.71,123.3281,214.334
EBITDA Ratio 0.1550.1690.2380.3010.2150.2010.1520.1480.110.1820.2320.2050.2240.2270.2210.1480.2170.2180.1490.179